Timing Event
1Q09      Event rate assesment (ipilimumab)

1Q09      EMEA approval (ustekinumab)

AACR 2009 Phase 1 interim data (MDX-1401) [anti-CD30]

2Q09      FDA approval (golimumab)

ASCO 2009 Interim Phase 1 single dose oncology results (MDX-1106) [anti-PD1]

ASCO 2009 Present updated overall survival data from the phase II ipilimumab melanoma trial

2Q09      EMEA approval (golimumab)

1H09      Interim Phase 2 RA data (MDX-1100)[anti-IP10]

mid-09    Phase 2 proof of concept data in ulcerative colitis and RA (MDX-1100) [anti-IP10]

2Q09/3Q09 FDA approval (ustekinumab)

2009      Initiate Phase 3 prostate cancer trial (ipilimumab)

4Q09      Interim Phase 1b multi-dose oncology results (MDX-1106) [anti-PD1]

4Q09      Phase 3 trial results - overall survival in 1st-line melanoma (ipilimumab)

2009      Phase 1 CLL & RA data (MDX-1342) [anti-CD19]

2009      Initiate Phase 1 (MDX-1203) [anti-Cd70 conjugate]

late-09/early-10 Phase 2 trial results - lung cancer (ipilimumab)

1H10      Potential BLA filing (ipilimumab)

1H10      Interim phase I data in solid tumors (MDX-1105)[anti-PD-L1]

2010      Phase 3 adjuvant data - melanoma (ipilimumab)